mcdermott: immunotherapy agents in renal cell carcinoma
Published 9 years ago • 55 plays • Length 1:08Download video MP4
Download video MP3
Similar videos
-
1:45
mcdermott: the questions immunotherapy trials aren't answering
-
1:44
immunotherapy of renal cell carcinoma
-
1:15
dr. mcdermott on single-agent versus combination immunotherapy in rcc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
2:07
dr. mcdermott on tki/immunotherapy combinations in rcc
-
0:54
dr. mcdermott on immunotherapy as a standard of care in rcc
-
58:31
audio version uronurse episode 106: new immunotherapy approaches for bladder cancer
-
1:58
dr. mcdermott on single-agent pembrolizumab in advanced rcc
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
21:35
the status of immunotherapy for metastatic renal cell carcinoma in 2012 david mcdermott, md
-
2:18
dr. mcdermott on immunotherapy-related aes in rcc
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
1:40
targeted therapies for renal cell carcinoma
-
1:02
dr. mcdermott on novel immunotherapy combinations in rcc
-
0:51
dr. mcdermott on pd-l1 expression in non-clear cell renal cell cancer
-
0:42
dr. mcdermott on targeting pd-1 and pd-l1 in kidney cancer
-
1:25
dr. mcdermott discusses pd-l1 expression in kidney cancer
-
1:53
dr. mcdermott on long-term benefit with nivolumab in rcc